Merck KGaA Announces Executive Board Change

Dr. Jan Sombroek to retire, Dr. Karl-Ludwig Kley will assume his duties

31-May-2006

Dr. Jan Sombroek, Member of the Executive Board of Merck KGaA and personally liable general partner, will retire at the end of 2006.

Dr. Sombroek (59) has been a Member of the Executive Board since 1997. He is currently responsible for the Group-wide Human Resources and Information Services functions as well as for the Pharmaceutical and Chemicals businesses in Latin America, India, Indonesia, Pakistan, the Philippines, Thailand and Vietnam. Externally, he is chairman of the Trade Association of Southern Hesse and treasurer of the German Chemical Society (GDCh). After earning a doctorate in Chemistry at the University of Cologne, Sombroek began his career with Merck in 1975 as the head of a laboratory in Medicinal Chemistry. In 1983, he was appointed Head of Cardiovascular within Medicinal Chemistry and in 1990 he took over the leadership of Medicinal Chemistry. After a research sabbatical at the National Institutes of Health (NIH) in Bethesda, Maryland, he returned to Darmstadt to become Head of Pharmaceutical Project Management and Head of Preclinical Research and Development in 1993.

Dr. Karl-Ludwig Kley, Vice Chairman of the Executive Board and personally liable general partner at Merck as of September 1, will take over Dr. Sombroek's responsibilities on January 1, 2007.

Elmar Schnee, Deputy Member of the Executive Board since November 2005 with responsibility for the Pharmaceuticals business sector, will become a full Member of the Executive Board and personally liable general partner as of July 1, 2006.

https://www.chemeurope.com/en/news/55157/merck-kgaa-announces-executive-board-change.html